Mario Boccadoro

Q: What Schools Are Affiliated With Mario Boccadoro

Mario Boccadoro is affiliated with the following schools: University of Catania, University of Milan, University of Parma, University of Verona, University of Florence, University of Turin, University of Salamanca, University of Bologna

Mario Boccadoro's AcademicInfluence.com Rankings

Mario Boccadoro

Computer Science

#6067

World Rank

#6397

Historical Rank

Machine Learning

#1843

World Rank

#1867

Historical Rank

Artificial Intelligence

#2093

World Rank

#2128

Historical Rank

Database

#3184

World Rank

#3318

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Mario Boccadoro's Degrees

PhD Computer Science University of Milan
Masters Computer Science University of Milan
Bachelors Computer Science University of Milan

Similar Degrees You Can Earn

Why Is Mario Boccadoro Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mario Boccadoro's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group (2003) (2143)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. (2005) (1965)
International staging system for multiple myeloma. (2005) (1929)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. (2016) (1536)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial (2006) (803)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management (2010) (660)
Autologous transplantation and maintenance therapy in multiple myeloma. (2014) (642)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis (2008) (556)
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. (1998) (520)
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. (2007) (515)
A comparison of allografting with autografting for newly diagnosed myeloma. (2007) (510)
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. (2003) (445)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. (2011) (406)
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. (2010) (404)
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. (1990) (375)
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma (1997) (372)
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. (2010) (370)
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. (2008) (368)
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). (2011) (328)
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. (2004) (320)
Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. (2007) (318)
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. (2011) (312)
C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. (1992) (310)
Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. (2004) (302)
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline (2009) (300)
Thalidomide for treatment of multiple myeloma: 10 years later. (2008) (296)
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. (2012) (292)
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. (2015) (278)
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. (2010) (270)
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. (2012) (266)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders (2014) (265)
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. (2011) (258)
Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. (1999) (247)
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. (2008) (243)
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway (2009) (242)
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. (2009) (235)
Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy (2005) (220)
Corticosteroids can reverse severe imatinib-induced hepatotoxicity. (2006) (216)
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. (2014) (198)
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma (2014) (191)
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. (2003) (185)
Low-dose thalidomide plus dexamethasone is effective as salvage therapy for advanced myeloma, (2001) (183)
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials (2013) (181)
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. (2007) (181)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study (2008) (180)
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. (2010) (177)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (2008) (173)
Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. (1999) (163)
High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. (1995) (160)
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2021) (156)
Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates (2008) (148)
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 stud (2020) (144)
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. (2007) (143)
Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. (1991) (136)
Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. (1993) (136)
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. (2014) (133)
Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy (2010) (133)
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. (2015) (132)
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. (2004) (129)
Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. (2004) (126)
Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas (1993) (120)
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. (1994) (116)
Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. (2008) (116)
Effector γδ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma (2005) (114)
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors (1997) (113)
Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2010) (113)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations (2008) (109)
The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation (2009) (108)
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR. (2015) (108)
AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition (2010) (108)
Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies (2006) (107)
A practical update on the use of bortezomib in the management of multiple myeloma. (2006) (104)
Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma (2020) (104)
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives (2017) (104)
Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy (1999) (100)
Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. (2009) (100)
Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. (2007) (98)
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) (2020) (98)
Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective (2010) (94)
European perspective on multiple myeloma treatment strategies in 2014. (2014) (92)
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy (1984) (91)
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up (2021) (91)
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. (2021) (90)
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. (2013) (87)
Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia (2013) (86)
Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. (2005) (86)
Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia (2009) (86)
Superior Complete Response Rate and Progression-Free Survival after Autologous Transplantation with up-Front Velcade-Thalidomide- Dexamethasone Compared with Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma (2008) (85)
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. (2016) (83)
Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. (2010) (83)
Diagnosis, prognosis, and standard treatment of multiple myeloma. (1997) (82)
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival (2014) (82)
Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. (2002) (82)
Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). (2004) (82)
Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma (2005) (81)
European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. (1994) (79)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. (2021) (78)
Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) (2007) (78)
Durable and complete hematopoietic reconstitution after autografting of rhGM-CSF exposed peripheral blood progenitor cells. (1990) (78)
Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis. (1989) (78)
Human myeloma cell lines as a tool for studying the biology of multiple myeloma: a reappraisal 18 years after. (1995) (77)
European perspective on multiple myeloma treatment strategies: update following recent congresses. (2012) (77)
Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA (2010) (77)
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. (2013) (77)
Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). (2007) (76)
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. (1999) (75)
Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) (2018) (75)
European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when (2018) (75)
Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia (2014) (74)
High‐dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma (2003) (74)
VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. (2004) (74)
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials (2013) (73)
Multiple myeloma: increased circulating lymphocytes carrying plasma cell-associated antigens as an indicator of poor survival. (1990) (71)
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. (2005) (71)
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network (2020) (70)
Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. (2019) (69)
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross-Talk between Vγ9Vδ2 T Cells, αβ CD8+ T Cells, Regulatory T Cells, and Dendritic Cells (2011) (69)
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. (2008) (67)
Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of monoclonal gammopathies: correlation with diagnosis and disease status. (1988) (67)
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy (2004) (67)
Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. (1995) (67)
The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation. (1989) (65)
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells (2011) (64)
Genome‐wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles (2013) (62)
A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs (2010) (62)
Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1‐like regulatory T cells (2005) (62)
Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial. (2005) (61)
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (2016) (61)
Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features (2004) (60)
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma (2006) (59)
Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
Reduced tumor growth after low-dose irradiation or immunization against blastic suppressor T cells. (1981) (58)
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA) (2018) (58)
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma (2015) (57)
Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network (2017) (57)
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. (2017) (57)
Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside (2005) (57)
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. (2006) (56)
Circulating miRNA markers show promise as new prognosticators for multiple myeloma (2014) (55)
Severe and long‐lasting disruption of T‐cell receptor diversity in human myeloma after high‐dose chemotherapy and autologous peripheral blood progenitor cell infusion (2001) (54)
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches (2010) (54)
Role of chemotherapy and GM-CSF on hemopoietic progenitor cell mobilization in multiple myeloma. (1993) (52)
Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome (2013) (52)
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma (2011) (52)
Detection of circulating tumor cells in multiple myeloma by a PCR-based method. (1993) (51)
A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients (2008) (51)
Multiple Myeloma Treatment in Real‐world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study (2018) (51)
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma (2001) (51)
Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma (1998) (50)
Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients (2007) (50)
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma. (2020) (49)
Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias (2009) (47)
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy (2011) (47)
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide (2006) (47)
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents (2016) (47)
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) (2018) (46)
Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. (2006) (46)
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. (2012) (45)
Autologous Stem Cell Transplantation Versus Bortezomib-Melphalan-Prednisone for Newly Diagnosed Multiple Myeloma: Second Interim Analysis of the Phase 3 EMN02/HO95 Study (2017) (45)
How to manage neutropenia in multiple myeloma. (2012) (45)
Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. (2004) (45)
Recombinant interferon alfa-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. (1988) (44)
High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib (2014) (44)
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma (2012) (44)
Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial (2020) (44)
Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia (2018) (43)
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis (2017) (43)
A Phase IB, Multi-Center, Open-Label Dose-Escalation Study of Oral Panobinostat (LBH589) and I.V. Bortezomib in Patients with Relapsed Multiple Myeloma. (2008) (42)
Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation. (2010) (42)
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. (2003) (42)
Melphalan and its role in the management of patients with multiple myeloma (2007) (42)
Oral Revlimid® Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma: Results of a Multicenter Phase I/II Study. (2006) (41)
Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients (2012) (41)
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy (2014) (41)
Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. (1988) (40)
Upfront Single Versus Double Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial) (2016) (40)
Kinetics of circulating B lymphocytes in human myeloma. (1983) (40)
Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma (2001) (40)
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma (2010) (40)
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial (2010) (40)
Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells. (1993) (39)
Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) (2020) (39)
A large-scale study of bone marrow involvement in patients with Hodgkin's lymphoma. (2004) (38)
Multiple myeloma: ‘early’ plasma cell phenotype identifies patients with aggressive biological and clinical characteristics (1993) (38)
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project (2022) (38)
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma (2016) (38)
Management of Multiple Myeloma with Bortezomib: Experts Review the Data and Debate the Issues (2007) (37)
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma (2018) (37)
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension (2019) (37)
Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. (2009) (37)
New drugs for treatment of multiple myeloma. (2004) (37)
Melphalan hydrochloride for the treatment of multiple myeloma (2017) (36)
Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients. (2009) (36)
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma (2014) (36)
Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma (NDMM) Patients: RV-MM-PI-0752 Phase III Randomized Study (2018) (36)
Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies (2018) (35)
Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients (2013) (35)
Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail. (2005) (35)
Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma (2019) (35)
N- and K-ras oncogenes in plasma cell dyscrasias. (1994) (34)
Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. (2011) (34)
Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2) (2004) (34)
Novel Immunotherapies for Multiple Myeloma (2017) (34)
Thalidomide–dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide–dexamethasone: a case‐matched study in advanced multiple myeloma (2007) (34)
Insights on Multiple Myeloma Treatment Strategies (2018) (33)
A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis. (2004) (33)
Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. (1990) (33)
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells (2015) (33)
Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. (2009) (32)
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant (2005) (32)
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network (2021) (32)
Immuno‐oncologic Approaches: CAR‐T Cells and Checkpoint Inhibitors (2017) (32)
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis (2016) (31)
A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients (2013) (31)
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. (2012) (31)
Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis (2018) (31)
The idiotypic specificities of lymphocytes in human monoclonal gammopathies: analysis with the fluorescence activated cell sorter. (1983) (31)
SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma (2012) (30)
Melphalan/Prednisone/Lenalidomide (MPR) Versus High-Dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Multiple Myeloma (MM) Patients <65 Years: Results of a Randomized Phase III Study (2011) (30)
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia (2020) (30)
Extracellular vesicles as potential biomarkers of acute graft-vs-host disease (2018) (28)
Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study (2018) (28)
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study) (2016) (28)
Human myeloma: Several subsets of circulating lymphocytes express plasma cell‐associated antigens (1988) (28)
Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. (2004) (27)
Idiotypic lymphocytes in human monoclonal gammopathies. (1981) (27)
Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis (2004) (27)
Multiple myeloma: biological and clinical significance of bone marrow plasma cell labelling index. (1987) (27)
Recombinant interferon‐γ inhibits the in vitro proliferation of human myeloma cells (1994) (27)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595)) (2008) (27)
Kaposi's sarcoma triggered by endogenous HHV‐8 reactivation after non‐myeloablative allogeneic haematopoietic transplantation (2006) (26)
Bortezomib-Doxorubicin-Dexamethasone as Induction Prior to Reduced Intensity Autologous Transplantation Followed by Lenalidomide as Consolidation/Maintenance in Elderly Untreated Myeloma Patients (2008) (26)
CD38 as an immunotherapeutic target in multiple myeloma (2018) (26)
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs (2019) (26)
Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype (1994) (26)
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents (2014) (26)
Unrelated donor haematopoietic cell transplantation after non‐myeloablative conditioning for patients with high‐risk multiple myeloma (2007) (26)
Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. (2007) (26)
Phase I Study of AVE1642 Anti IGF-1R Monoclonal Antibody in Patients with Advanced Multiple Myeloma. (2007) (26)
Standard chemotherapy for myelomatosis: an area of great controversy. (1992) (26)
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial (2019) (26)
Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). (2019) (25)
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. (2020) (25)
Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies (2019) (25)
A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (25)
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status (2014) (25)
Dose/Schedule-Adjusted Rd-R vs Continuous Rd for elderly, intermediate-fit, newly diagnosed multiple myeloma patients. (2021) (25)
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial (2019) (24)
Reactive plasmacytosis. Case report and review of the literature. (1985) (24)
Polyclonal Immunoglobulin E Levels Are Correlated with Hemoglobin Values and Overall Survival in Patients with Multiple Myeloma (2007) (24)
Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing (2020) (24)
Emerging drugs and combinations to treat multiple myeloma (2017) (24)
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines (2021) (24)
Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients (2012) (24)
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma (2018) (24)
Chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in elderly versus non-elderly cancer patients: Patterns, outcomes, and determinants (MONITOR-GCSF study). (2017) (23)
Multiple Myeloma Plasma Cell Kinetics: Rapid and Reliable Evaluation using 5-Bromo-2-Deoxyuridine (BrdUrd) DNA Incorporation Detected by an Anti-BrdUrd Monoclonal Antibody (1986) (23)
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study (2014) (23)
A Phase III Study of Enoxaparin vs Aspirin vs Low-Dose Warfarin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Thalidomide Based-Regimens. (2009) (23)
Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study. (2004) (23)
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial (2021) (23)
Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. (2006) (23)
HIF-1α is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia (2019) (23)
DISTRIBUTION OF T‐CELL SIGNALLING MOLECULES IN HUMAN MYELOMA (1997) (23)
Defective interleukin‐2 induction of lymphokine‐activatedkiller (LAK) activity in peripheral blood T lymphocytesof patients with monoclonal gammopathies (1990) (22)
Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. (2006) (22)
The generation of alloreactive cytotoxic T lymphocytes requires the expression of ecto-5'nucleotidase activity. (1988) (22)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial (2018) (22)
Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. (2000) (22)
1Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis (1995) (22)
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients (2014) (22)
Primary plasma cell leukemia in the era of new drugs: has something changed? (2012) (22)
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. (2006) (22)
A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens (2008) (22)
Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. (2013) (21)
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts (2009) (21)
Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials (2018) (21)
Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs (2015) (21)
Conventional induction treatments do not influence overall survival in multiple myeloma (1997) (21)
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age (2013) (21)
Efficacy of a combination of human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes (2009) (21)
Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial (2006) (21)
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multip (2015) (21)
Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors (2010) (21)
European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma (2021) (21)
Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high‐dose chemotherapy courses (1997) (20)
Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support (2000) (20)
Oral lenalidomide plus melphalan and prednisone (R-MP) for newly diagnosed multiple myeloma. (2006) (20)
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. (2013) (20)
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report (2016) (20)
Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma (2013) (20)
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. (2018) (20)
Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients (2013) (20)
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. (2021) (20)
Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients (1997) (20)
Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). (2017) (20)
Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests. (2002) (20)
Consolidation with Bortezomib, Thalidomide and Dexamethasone Induces Molecular Remissions in Autografted Multiple Myeloma Patients (2007) (19)
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies (2014) (19)
Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies (2019) (19)
Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. (2011) (19)
The impact of response on bone-directed therapy in patients with multiple myeloma. (2013) (19)
Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation (2015) (18)
Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial (2020) (18)
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. (2003) (18)
Treatment of multiple myeloma: a randomized study of three different regimens. (1985) (18)
Increased serum neopterin concentration as indicator of disease severity and poor survival in multiple myeloma (1991) (18)
The use of erythropoiesis‐stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib (2018) (18)
Hematologic Profiles in the Phase 3 APEX Trial. (2005) (18)
AT7519, a Novel Small Molecule Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma VIA GSK3β (2008) (18)
Retinoic acid inhibits the growth of human myeloma cells in vitro (1995) (18)
Time to first disease progression, but not β2‐microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy (2007) (18)
A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients. (2006) (18)
Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma. (2018) (18)
The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib‐containing regimens (2011) (18)
Increased expression of non‐functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients (2000) (18)
Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. (2011) (18)
Multiple myeloma: altered CD4/CD8 ratio in bone marrow. (1990) (18)
Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study (2017) (18)
Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial. (2017) (18)
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. (2006) (17)
Pomalidomide Cyclophosphamide and Prednisone (PCP) Treatment for Relapsed/Refractory Multiple Myeloma (2012) (17)
Lack of correlation between plasma cell thymidine labelling index and serum beta-2-microglobulin in monoclonal gammopathies. (1987) (17)
Decreasing Frequency of Osteonecrosis of the Jaw in Cancer and Myeloma Patients Treated with Bisphosphonates: The Experience of the Oncology Network of Piedmont and Aosta Valley (North-Western Italy) (2013) (17)
Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs (2020) (17)
Erratum: Myeloma management guidelines: A consensus report from the scientific advisors of the international myeloma foundation (The Hematology Journal (2003) vol, 4 (379-398) 10.1038/sj.thj.6200312) (2004) (17)
A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (17)
BRAF gene is not mutated in plasma cell leukemia and multiple myeloma (2003) (16)
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials (2020) (16)
Multiple myeloma: ecto-5' nucleotidase deficiency of suppressor/cytotoxic (CD8) lymphocytes is a marker for the expansion of suppressor T cells. (1987) (16)
Lenalidomide and its role in the management of multiple myeloma (2008) (16)
A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients. (2009) (16)
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma (2013) (16)
Multiple independent immunoglobulin class‐switch recombinations occurring within the same clone in myeloma (1992) (16)
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network (2019) (16)
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma (2010) (16)
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma. (2004) (16)
Emerging drugs and combinations to treat multiple myeloma. (2017) (16)
Altered expression of growth-regulated protooncogenes in human malignant plasma cells. (1989) (16)
Human myeloma: kinetics of the remission phase. (1982) (15)
A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide (2011) (15)
INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma (2019) (15)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US (2021) (15)
A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma: Analysis of Mature Data from 7077 Patients Collected By European Myeloma Network within Harmony Big Data Platform (2020) (15)
Can pegylated interferon improve the outcome of polycythemia vera patients? (2017) (15)
Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. (1994) (15)
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M 2 ) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis. (2009) (15)
Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. (2011) (15)
Patients with high‐risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting (2003) (15)
Treatment of newly diagnosed multiple myeloma (2008) (15)
Review of thalidomide in the treatment of newly diagnosed multiple myeloma (2007) (15)
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes (2012) (15)
Multiple myeloma: beta-2-microglobulin is not a useful follow-up parameter. (1989) (15)
GM-CSF-exposed peripheral blood progenitors as sole source of stem cells for autologous transplantation in two patients with multiple myeloma. (1990) (15)
Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter’s Syndrome Transformation in Chronic Lymphocytic Leukemia. (2008) (14)
Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small‐ and large‐scale Miltenyi cell sorting system (2002) (14)
Telomeres and telomerase in normal and malignant B‐cells (2010) (14)
High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors (2003) (14)
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials (2019) (14)
Myeloma and related disorders. (1994) (14)
Early recruitment in the human myeloma cell population after cytostatic treatment. (1976) (14)
Major Shrinking of Residual Tumor Cell Burden and Achievement of Molecular Remissions in Myeloma Patients Undergoing Post-Trasplant Consolidation with Bortezomib, Thalidomide and Dexamethasone: A Qualitative and Quantitative PCR Study (2008) (14)
Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma (2013) (14)
TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS (2003) (14)
Velcade™ Plus Melphalan, Prednisone, and Thalidomide (V-MPT) for Advanced Multiple Myeloma. (2005) (14)
Interferon plus glucocorticoids as intensified maintenance therapy prolongs tumor control in relapsed myeloma. (1993) (14)
Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients (2019) (13)
Systemic virotherapy for multiple myeloma (2017) (13)
New developments and treatment in multiple myeloma: new drugs in the treatment of multiple myeloma. (2002) (13)
Cells carrying nonlymphoma-associated bcl-2/IgH rearrangements (NLABR) are phenotypically related to follicular lymphoma and can establish as long-term persisting clonal populations. (2006) (13)
Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma (2021) (13)
How is patient care for multiple myeloma advancing? (2017) (13)
Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status (2010) (13)
Interferon-? in Multiple Myeloma (1995) (13)
Academic promotion in Italy (1992) (13)
Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study (2020) (13)
Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. (2021) (12)
Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia (2011) (12)
Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials (2017) (12)
PF586 SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY (2019) (12)
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives. (2019) (12)
Mutational Activation of Nand Kras Oncogenes in Plasma Cell Dyscrasias (2003) (12)
Classification of patients affected by multiple myeloma using a neural network software (1994) (12)
Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). (2020) (11)
A new standard of care for elderly patients with myeloma (2007) (11)
Bortezomib-Based Induction Treatments Improve Outcomes of Newly Diagnosed Multiple Myeloma Patients with High-Risk Cytogenetic Abnormalities (2010) (11)
Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? (1993) (11)
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study (2019) (11)
Cost of Illness in Patients with Multiple Myeloma in Italy: The CoMiM Study (2013) (11)
Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in human monoclonal gammopathies: correlation with tumor cell kinetics. (1985) (11)
Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients (2011) (11)
Multiple myeloma: Intensified maintenance therapy with recombinant interferon‐α‐2b plus glucocorticoids (1992) (11)
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True (2020) (11)
Emergence of activated lymphocytes in CD4 and CD8 subpopulations of multiple myeloma: correlation with the expansion of suppressor T-cells (CD8+ OKM1+) and ecto-5'nucleotidase deficiency. (1988) (11)
LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL (2011) (11)
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies (2020) (11)
Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation (2003) (11)
Investigational treatments for multiple myeloma (2006) (11)
A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma (2013) (11)
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. (2019) (10)
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma (2010) (10)
Plasma cell dyscrasias: classification, clinical and laboratory characteristics, and differential diagnosis. (1995) (10)
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents (2020) (10)
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia (2016) (10)
Current therapeutic options for multiple myeloma. (1996) (10)
Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives (2020) (10)
Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study. (2005) (10)
Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients (2020) (10)
Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated “same-day” (< 24 h), “per-guidelines” (24–72 h), and “late” (> 72 h): findings from the MONITOR-GCSF study (2018) (10)
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long‐lasting imatinib discontinuation? A real life experience (2017) (10)
Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity (2020) (10)
Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials. (2018) (10)
Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. (2012) (10)
A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients (2010) (10)
Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma (2018) (10)
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data (2017) (10)
Evaluation of the pharmacokinetics, preclinical, and clinical efficacy of lenalidomide for the treatment of multiple myeloma (2012) (10)
An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. (1999) (10)
Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial (2008) (10)
AgNORs and myeloma prognosis. (1994) (10)
CD3‐induced T‐cell activation in the bone marrow of myeloma patients: major role of CD4+ cells (1995) (10)
Bortezomib, Melphalan, Prednisone and Thalidomide (Vmpt)versus Bortezomib, Melphalan and Prednisone (Vmp) Inelderly Newly Diagnosed Myeloma Patients: A Prospective,randomized, Phase Iii Study (2009) (10)
First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. (2009) (9)
Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma. (2005) (9)
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment (2012) (9)
Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis (2019) (9)
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma (2019) (9)
High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments (2001) (9)
A phase III trial of melphalan/prednisone/lenalidomide (MPR) versus melphalan (200 mg/m2) and autologous transplantation (MEL200) in newly diagnosed myeloma patients. (2010) (9)
Cost of illness in patients with multiple myeloma in Italy: the CoMiM study. (2013) (9)
Determining treatment intensity in elderly patients with multiple myeloma (2018) (9)
A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens. (2007) (9)
Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: Updated results. (Blood (2013) 122, 8 (1376-1383)) (2014) (9)
Recombinant interferon-gamma inhibits the in vitro proliferation of human myeloma cells. (1994) (9)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group (2022) (9)
Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting) (2016) (9)
Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the european myeloma network. (2017) (9)
Dysfunctional V 9 V 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells * (2012) (9)
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (MM) Patients (2016) (9)
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients (2010) (9)
Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. (2005) (9)
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (2022) (9)
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen. (2010) (8)
Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma patients (2004) (8)
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma (2021) (8)
Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL (2021) (8)
Bortezomib, Pegylated-Lyposomal-Doxorubicin and Dexamethasone Followed by Melphalan 100 mg/m2 in Elderly Newly Diagnosed Patients: An Interim Analysis. (2007) (8)
Trichoderma species fungemia after high‐dose chemotherapy and autologous stem cell transplantation: a case report (2014) (8)
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response (2018) (8)
Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network (2020) (8)
Magic pills: new oral drugs to treat chronic lymphocytic leukemia (2017) (8)
Antibiotic Prophylaxis Before Dental Procedures Can Reduce ONJ Incidence. (2007) (8)
Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial (2020) (8)
Bortezomib, pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous stem cell transplant (ASCT) followed by lenalidomide and prednisone (LP) as consolidation and lenalidomide alone as maintenance (2008) (8)
MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial (2019) (8)
Immunomodulatory and clinical effects of daratumumab in T‐cell acute lymphoblastic leukaemia (2020) (8)
Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid. (2005) (8)
Long‐term follow‐up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13‐cis‐retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival (2012) (8)
High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission (2006) (8)
The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy. (2009) (8)
Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints. (2014) (8)
Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCd) in Newly Diagnosed Multiple Myeloma Patients: A Phase I- II Study (2014) (7)
Plasma cell acid phosphatase activity as prognostic factor in multiple myeloma: relationship to the thymidine-labeling index. (1985) (7)
Next-Generation Sequencing and Real-Time Quantitative PCR for Minimal Residual Disease (MRD) Detection Using the Immunoglobulin Heavy Chain Variable Region: A Methodical Comparison in Acute Lymphoblastic Leukemia (ALL), Mantle Cell Lymphoma (MCL) and Multiple Myeloma (MM) (2012) (7)
Autologous Transplantation Versus Cyclophosphamide-Lenalidomide-Prednisone Followed By Lenalidomide-Prednisone Versus Lenalidomide Maintenance in Multiple Myeloma: Long-Term Results of a Phase III Trial (2015) (7)
Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study (2013) (7)
Analysis of immunoglobulin heavy chain gene rearrangement using the polymerase chain reaction. (1992) (7)
Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients. (2007) (7)
Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated (2017) (7)
Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results (2008) (7)
Generation of anti‐tumour activity by OKT3‐stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis (1994) (7)
A Prospective Randomized Phase I/II Study of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) for Relapsed/Refractory Multiple Myeloma Patients. (2009) (7)
Cell-Free DNA for Minimal Residual Disease Monitoring in Multiple Myeloma Patients (2014) (7)
Talk between V Human Myeloma : An Advantageous Cross Immune Modulation by Zoledronic Acid in (2011) (7)
Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial. (2018) (7)
Clinicopathologic spectrum of cutaneous diseases in patients with hematologic malignancies with or without allogeneic bone marrow transplantation: an observational cohort study in 101 patients. (2013) (7)
Real-time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in myeloma. (2005) (7)
Early Mortality in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Agents (2015) (7)
High-Risk Cytogenetics in Newly Diagnosed Multiple Myeloma: Prognostic Relevance of Co-Segregations and Analysis of the Role of Double Versus Single Autotransplantation (2017) (7)
A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol (2018) (7)
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (2020) (7)
Role of allogeneic stem cell transplantation in multiple myeloma. (2009) (7)
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis (2018) (7)
Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: Analysis of over 3,000 Pts from the Insight MM Global, Prospective, Observational Study (2019) (7)
Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone. (2009) (6)
Phenotypic and functional analysis of peripheral blood lymphocytes during interferon-alpha 2b therapy in multiple myeloma patients with low tumor mass. (1991) (6)
FLAI induction regimen in elderly patients with acute myeloid leukemia (2019) (6)
Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma (2015) (6)
Cyclophosphamide (3.6 g/m2) therapy with G-CSF support for resistant myeloma. (1994) (6)
Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes. (2019) (6)
Monitoring of a Long Survival Myeloma Patient (1981) (6)
Relevance of sample preparation for flow cytometry (2018) (6)
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front‐line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients (2013) (6)
Dual rearrangement of immunoglobulin and T‐cell receptor gene in a case of T‐cell hairy‐cell leukemia (1991) (6)
HIF-1฀ is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia (2021) (6)
Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. (2019) (6)
Melphalan, Thalidomide and Prednisone (MPT) Combined with Oral Panobinostat In Patients with Relapsed/Refractory MM: a Phase I-II Study (2010) (6)
Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials (2017) (6)
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (6)
Double Autologous Transplant Versus Tandem Autologus - Non Myeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma. (2005) (6)
Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma patients. (2004) (5)
Impact of Autologous Transplantation Vs. Chemotherapy Plus Lenalidomide in Newly Diagnosed Myeloma According to Patient Prognosis: Results of a Pooled Analysis of 2 Phase III Trials (2014) (5)
Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients. (2010) (5)
Monoclonal Immunoglobulin Gene Rearrangement in Peripheral Lymphocytes of a Patient with Multiple Myeloma (1989) (5)
Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma (2017) (5)
Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study (2014) (5)
S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS (2019) (5)
Lenalidomide, melophalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma (2008) (5)
The Future Role of Thalidomide in Multiple Myeloma (2005) (5)
Role of thalidomide in previously untreated patients with multiple myeloma (2008) (5)
Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma (2002) (5)
Retrospective analysis of the long term safety of lenalidomide (Len)±dexamethasone (Dex) in relapsed/refractory multiple myeloma (RRMM) patients (pts): analysis of pooled data and incidence rates (IR) of second primary malignancy (SPM) (2011) (5)
Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial. (2006) (5)
Analysis of the breakpoint cluster region in essential thrombocythemia. (1990) (5)
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. (2007) (5)
Defibrotide (DF), an Orally Bioavailable Modulator of Myeloma Tumor-Microenvironment Interactions: Molecular Sequelae and Clinical Implications. (2006) (5)
Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). (2013) (5)
Data quality improvement of a multicenter clinical trial dataset (2017) (5)
Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study (2017) (5)
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. (2021) (5)
A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients (2017) (5)
Immune dysregulation in monoclonal gammopathies. (1989) (5)
Serum Free Light Chain Ratio , Total / Ratio , and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (2009) (4)
Infection Complications in 476 Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide or Bortezomib Combinations (2015) (4)
Biomarkers of Acute Graft-Versus-Host Disease: Surface Antigens and Micro Rnas in Extracellular Vesicles (2019) (4)
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study (2010) (4)
Defibrotide Counteracts the Modifications of Anti-Thrombotic Phenotype of Endothelial Cells Induced by Thalidomide. (2007) (4)
Update on Recent Developments for Patients with Newly Diagnosed Multiple Myeloma (2008) (4)
Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM (2014) (4)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial (2021) (4)
Time to First Progression, but Not Β2-Microglobulin, Predicts Outcome in Myeloma Patients Who Received Thalidomide as Salvage Therapy. (2006) (4)
Correlation between argyrophilic nucleolar organizer region counts and labelling index in multiple myeloma (2009) (4)
Defibrotide: a review on clinical use and future development. (2008) (4)
Bortezomib and Dexamethasone as Maintenance therapy in Relapse/Refractory multiple myeloma Patients (2008) (4)
Prognostic Evaluation of Myelodysplastic Syndromes (MDS): Analysis of Deaths Due to Age-Related Causes. (2005) (4)
Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS. (2006) (4)
Immunologic characteristics of fibrillary glomerulonephritis. (1992) (4)
PCR-based monitoring of residual myeloma cells in patients undergoing high-dose chemotherapy (1998) (4)
Concurrent G-CSF and GM-CSF administration for the induction of bone marrow-derived cell mobilization in patients with acute myocardial infarction: a pilot study evaluating feasibility, safety and efficacy. (2006) (4)
Discovering the Meaning of Monoclonal Gammopathy of Undetermined Significance: Current Knowledge, Future Challenges (2014) (4)
Interferon-gamma in multiple myeloma. (1995) (4)
Benign monoclonal gammopathy presenting with severe renal failure. (2009) (4)
Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients (2019) (4)
SERUM FREE LIGHT CHAINS (SFLC) ASSAY: A SUGGESTIVE NEW CRITERIA FOR EVALUATING DISEASE RESPONSE, PROGRESSION AND RELAPSE IN PLASMA-CELL DISORDERS (PD) AND A PROGNOSTIC FACTOR IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) (2006) (4)
Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients (2013) (4)
Extended half‐life rFIX in major surgery—How to improve clinical practice: An intraindividual comparison (2020) (4)
Cell kinetics of multiple myeloma. (1987) (4)
Targeted Locus Amplification (TLA): A Novel Next Generation Sequencing (NGS) Technology to Detect New Molecular Markers and Monitoring Minimal Residual Disease (MRD) in Mantle Cell and Follicular Lymphoma (2017) (4)
Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy (2016) (4)
Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study (2015) (4)
Benefit of Rituximab Addition to High-Dose Programs with Autograft for B-Cell Lymphoma: A Multicenter GITIL Survey on 957 Patients. (2006) (4)
Effectiveness and Safety of Ixazomib-Based Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated Outside the Clinical Trial Setting Via an Early Access Program (EAP) in Europe: Second Interim Analysis of the 'Use Via Early Access to Ixazomib' (UVEA-IXA) Study (2020) (3)
of Monoclonal Gammopathies: Correlation With Diagnosis and Disease Status (2016) (3)
Long‐term therapy‐free remission in a patient with platelet‐derived growth factor receptor beta‐rearranged myeloproliferative neoplasm (2016) (3)
Defibrotide: a review on clinical use and future development (2008) (3)
A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study: MM‐230 (2018) (3)
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients (2021) (3)
Car fi lzomib , cyclophosphamide , and dexamethasone in patients with newly diagnosed multiple myeloma : a multicenter , phase 2 study (2014) (3)
Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study (2017) (3)
Impact of baseline renal function on efficacy and safety of daratumumab plus bortezomib-melphalan-prednisone (VMP) in patients (Pts) with newly diagnosed multiple myeloma (NDMM) ineligible for transplantation (ALCYONE). (2018) (3)
Cytobiological studies in multiple myeloma. (1987) (3)
Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma (2013) (3)
Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial (2020) (3)
A retrospective study of R‐DHAP/Ox for early progressing follicular lymphoma (2018) (3)
The treatment of the elderly multiple myeloma patients (2007) (3)
Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis (2004) (3)
Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score (2021) (3)
Sequential Therapy with IMID's in Relapsed-Refractory Multiple Myeloma Patients. (2009) (3)
WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (WKCYD) FOLLOWED BY MAINTENANCE WITH WEEKLY CARFILZOMIB (WK) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) (2016) (3)
THE MUTATION OF N‐RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA (1993) (3)
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia (2018) (3)
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial (2022) (3)
Highly sensitive MYD88L265P mutation detection by droplet digital PCR in Waldenström Macroglobulinemia (3)
Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial. (2005) (3)
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma (2021) (3)
A PROSPECTIVE PHASE II STUDY ON TANDEM AUTOGRAFTING-ONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL RESULTS OF A MULTICENTER GITMO (GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO) PROTOCOL (2007) (3)
IMMUNOPHENOTYPIC RESPONSE AFTER ALLOGRAFTING IN MULTIPLE MYELOMA (2013) (3)
New drugs in early development for treating multiple myeloma: all that glitters is not gold (2020) (3)
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) (2018) (3)
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials (2022) (3)
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: evidences from long term follow‐up (2018) (3)
Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. (1989) (3)
Bortezomib-Thalidomide-Dexamethasone Incorporated Into Autotransplantation Is Associated with More Favorable Outcomes After Relapse in Comparison with Thalidomide-Dexamethasone Plus Autotransplantation in Multiple Myeloma (2012) (3)
Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens. (2009) (3)
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients (2021) (3)
Advances in biology of multiple myeloma: Cell kinetics, molecular biology and immunology (1989) (3)
A Multi-Center Phase I/II Study of Melphalan, Prednisone, Thalidomide and Defibrotide in Avanced Multiple Myeloma Patients. (2006) (3)
Frontline High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Stem Cell Transplantation Induces High Rates of Complete Response and Prolongs Survival in Mantle Cell Lymphoma (MCL). (2006) (3)
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics (2019) (3)
Multiple myeloma: a tailored therapy for elderly patients. (1993) (3)
Cytokinetic studies in human myeloma. (1986) (2)
Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]. (2021) (2)
Factors predictive of outcome in relapsed, refractory multiple myeloma patients treated with bortezomib, melphalan, prednisone, and thalidomide (VMPT) (2007) (2)
An update of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. (2007) (2)
Granulocyte-Macrophage Progenitors (GMPs) Express Low Adhesive Potential and High CXCR-4 Levels (2013) (2)
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. (2016) (2)
In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide (2014) (2)
Dipyridamole in vitro suppresses the generation of T‐cell cytotoxic functions: Synergistic activity with cyclosporine (1991) (2)
A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES (2010) (2)
Improved IgH-based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR in MCL and MM (2013) (2)
Sequential Approach with Bortezomib as Induction Before Autologous Transplantation, Followed by Lenalidomide as Consolidation-Maintenance in Untreated Multiple Myeloma Patients. (2009) (2)
Delphi, a Data Warehouse to Discover Associations between Variables in Clinical Trials: Application to the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial (2017) (2)
Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation (2020) (2)
Telomerase Inhibitor BIBR1532 Induces Telomere Shortening and Growth Inhibition in Extra-Germinal Center (GC)-Derived Lymphoid Cell Lines. (2004) (2)
Validation and Improvement Opportunities of the Revised International Staging System for Multiple Myeloma: An Analysis on Mature Data from European Clinical Trials within the Harmony Big Data Platform (2019) (2)
Early disappearance of murine plasmocytoma stem cells in long-term bone marrow culture. (1992) (2)
B lymphocytes receptors: a new biological approach for immunofluorescence studies. (1977) (2)
LIMITED GRAFT-VERSUS MYELOMA EFFECT AFTER LOW-DOSE TBI BASED NON-MYELOABLATIVE ALLOGRAFTING EMPLOYED AS SALVAGE TREATMENT COMPARED TO FIRST LINE TREATMENT (2006) (2)
Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity (2016) (2)
ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS (2010) (2)
Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study (2022) (2)
Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease (2016) (2)
The Degree of Telomere Loss in Hematopoietic Cells Correlates with the Risk of Secondary Myelodysplasia/Acute Leukemia Development Following Autologous Stem Cell Transplantation. (2007) (2)
Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). (2018) (2)
Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. (2020) (2)
Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Remain Comparable to the Outcomes Reported in the Phase 3 Tourmaline-MM1 Study (2019) (2)
Long-Term Follow-Up of the Randomized GITMO/IIL Trial Comparing CHOP-Rituximab vs. High-Dose Therapy with Rituximab (R-HDS) in High Risk Follicular Lymphoma (Fl): Updated Results Suggest the Use of R-HDS as Salvage Treatment. (2007) (2)
Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study (2018) (2)
Impact of Early Consolidation with Bortezomib, Thalidomide and Dexamethasone on Molecularly-Detectable Disease in MM Patients in CR or VGPR Following Autologous Transplantation: Uncommon Achievement of Molecular Remission Despite Evidence of Tumor Load Reduction by Real Time PCR. (2006) (2)
Contribution photo (2016) (2)
Updated analysis of CALGB (Alliance) 100104. (2017) (2)
Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study (2008) (2)
Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network (2021) (2)
Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques. (2006) (2)
[Human myeloma]. (1977) (2)
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy (2021) (2)
Long-Term Thymic Function and Reconstitution of the T Cell Compartment after T Cell-Replete Haplo-Identical Allografting (2019) (2)
PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US (2019) (2)
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial (2021) (2)
A look at treatment strategies for relapsed multiple myeloma (2018) (2)
Efficacy and Safety of Ixazomib Induction and Maintenance in Newly Diagnosed Multiple Myeloma Patients According to the IMWG Frailty Score: A Post-Hoc Analysis of the EMN10-Unito Trial (2020) (2)
Definition of RAEB-I and RAEB-Ii According to the Who Classification of Myelodysplastic Syndromes (MDS): Problems Emerging from a Large Multicenter Registry. (2004) (2)
Recombinant interferon-? in a patient with multiple myeloma (1994) (2)
Biology of the human myeloma cell population. I.Macromolecular characteristics. (1978) (2)
Circulating Mir-130a in Multiple Myeloma and Extramedullary Myeloma Patients (2014) (2)
Biosimilar Filgrastim Initiation in Patients Enrolled in the Monitor G-CSF Observational Study Relative to EORTC Guidelines (2012) (2)
Alpha‐2b recombinant interferon (Intron‐A) as maintenance treatment in multiple myeloma (1990) (2)
Droplet Digital PCR Assay for MYD88L265P: Clinical Applications in Waldenström Macroglobulinemia (2020) (2)
Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma (2017) (2)
Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study (2015) (2)
Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (2)
Bortezomib and Plasma Cell Leukemia. (2006) (2)
A Novel Digital Pcr Assay for Myd88 L265p Mutation Detection in Waldenstrom Macroglobulinemia: Minimal Residual Disease Monitoring and Characterization on Circulating Free Dna (2016) (1)
Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy. (1990) (1)
Early B lymphocytes in man (1980) (1)
Outcome of treatment for first versus later relapse in multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study (2015) (1)
Ixazomib-Based Induction Followed By Single-Agent Ixazomib Maintenance in Transplant Ineligible, Newly Diagnosed Multiple Myeloma Patients: Updated Results of the EMN10-Unito Trial (2020) (1)
Clinical and Biological Early Relapse Predictors in Multiple Myeloma: An Analysis from the MMRF CoMMpass Study (2019) (1)
Hematological Testing Is Not Required with Every Dose of Bortezomib In Patients with Adequate Blood Counts at the Start of Each Cycle (2010) (1)
Biochemical evidence for the presence of abnormal B lymphocytes in the peripheral blood of multiple myeloma patients. (1987) (1)
cell-associated antigens as an indicator of poor survival Multiple myeloma: increased circulating lymphocytes carrying plasma (2011) (1)
High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma (2012) (1)
Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma (2014) (1)
Should high-risk smouldering multiple myeloma be treated? (2020) (1)
Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset (2019) (1)
EXPRESSION OF MET MRNA AS PROGNOSTIC MARKER IN MULTIPLE MYELOMA PATIENTS TREATED WITH NOVEL DRUGS (2010) (1)
A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia. (2009) (1)
Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study (2008) (1)
OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study (2021) (1)
Cytofluorimetric evaluation of plasma cell proliferative activity in monoclonal gammopathies. (1997) (1)
Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry (2011) (1)
Regulatory T Cells (Tregs) Are Highly Preserved in Multiple Myeloma Patients and Can Dominate Effector Functions. (2006) (1)
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma (2022) (1)
Impact of Complete Response on Survival with Either Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Pooled Analysis of 5 Phase III Trials in Newly Diagnosed Multiple Myeloma Patients (2015) (1)
Thromboprophylaxis for Newly Diagnosed Multiplemyeloma Patients Treated With Lenalidomide-Basedregimens: A Randomized Phase Iii Study of Aspirinvs Enoxaparin (2011) (1)
Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia (2018) (1)
Achievement of Complete Response Is a Strong Prognostic Factor In Elderly Newly Diagnosed Myeloma: Retrospective Analysis of 1175 Patients (2010) (1)
Qualitative and Quantitative Molecular Follow up of Minimal Residual Disease after Non Myeloablative Allografting for Multiple Myeloma. (2004) (1)
Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs (2019) (1)
of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report (2012) (1)
Melphalan 200 Mg/m 2 (Mel200) Versus Melphalan 100 Mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study (2008) (1)
Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years (2022) (1)
Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95) (2020) (1)
DVRd Followed By Ciltacabtagene Autoleucel Versus DVRd Followed By ASCT in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6) (2022) (1)
Impact of Treatment Intensification According to Patient Prognosis: A Pooled Analysis of 3 Randomized Phase III Trials (2016) (1)
REAL TIME QUANTITATIVE PCR SHOWS THAT PERIPHERAK BLOOD STEM CELL (PBPC) HARVESTS ARE SIGNIFICANTILY LESS CONTAMINATED THAN BONE MARROW (BM) IN MULTIPLE MYELOMA PATIENTS (MM). (1996) (1)
MOLECULAR REMISSION IN A MULTIPLE MYELOMA PATIENT AFTER A NON MYELOABLATIVE ALLOGENEIC TRANSPLANT: PROOF OF PRINCIPLE (2001) (1)
Highly Sensitive Droplet Digital PCR for MYD88L265P Mutation Detection and Minimal Residual Disease Monitoring in Waldenström Macroglobulinemia (2015) (1)
Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study (2021) (1)
Growth kinetics of minimal tumour masses: implications for rational chemotherapy. (1981) (1)
An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials (2016) (1)
Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). (2006) (1)
Retrospective Analysis Of 204 Patients With Polycythemia VERA: The International Working Group For Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) Prognostic Score Is A Good Predictor Of Survival and Prognosis (2013) (1)
NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY (2017) (1)
Multiple Myeloma and Related Disorders (2004) (1)
Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY (2016) (1)
[Prognostic factors in multiple myeloma]. (1989) (1)
Telomere Length Identifies Two Distinct Populations with Different Outcome among VH-Unmutated CLL Patients (2005) (1)
Allogenic stem cell transplantation following non-myeloablative conditioning regimens as adoptive immunotherapy in patients with hematological malignancies. (2002) (1)
Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma. (2006) (1)
A Phase I/II Trial on Melphalan, Prednisone, Thalidomide and Defribotide Combination in Relapsed/Refractory Multiple Myeloma Patients. (2007) (1)
Second-generation Proteasome Inhibition: What a Difference a Generation Makes (2015) (1)
512PChemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim in solid tumours versus haematological malignancies: Patterns, outcomes and determinants (MONITOR-GCSF study) (2017) (1)
Frontline induction therapy for multiple myeloma (MM) in real-world clinical practice: Third interim analysis of the multinational, observational EMMOS study (NCT01241396) (2015) (1)
Upfront Tandem Auto-Allo Transplant in Multiple Myeloma: Long-Term Follow-Up and Impact of “New Drugs” at Relapse (2017) (1)
The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations . (2008) (1)
Salvage treatment with pomalidomide-cyclophosphamide prednisone produces similar outcomes as compared to prior therapies in patients with relapsed/refractory multiple myeloma (2013) (1)
Long-Term Outcomes and Health-Related Quality of Life (HRQoL) By Response Status for Bortezomib, Melphalan, and Prednisone (VMP) ± Daratumumab (DARA) in Alcyone (2020) (1)
Physicians Poster SessionsPoster Session / Day 1 (2015) (1)
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) (2011) (1)
Continuous treatment improves survival of newly diagnosed multiple myeloma patients achieving complete response: data from 5 phase III trials including young and elderly patients (2015) (1)
Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs (2016) (1)
Negative Selective Pressure Exerted By Maintenance Therapy Promotes the Extinction of Sub-Clones Carrying High-Risk Lesions in Multiple Myeloma (2019) (1)
9200 ORAL A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM) (2011) (1)
P010 Incidence and risk factors of secondary myelodysplastic syndrome/acute leukemia occurrence following peripheral blood progenitor cell autograft: a GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) survey on 1266 lymphoma patients (2007) (1)
Immune Checkpoint Blockade Combinations As Promising Strategy for Cancer Immunotherapy in Multiple Myeloma Patients (2016) (1)
Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years (2022) (1)
A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity. (2010) (1)
Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD) (2011) (1)
Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs (2010) (1)
PCN49 COSTS AND QUALITY OF LIFE OF MULTIPLE MYELOMA (MM) IN ITALY: THE CO.MI.M. STUDY (2009) (1)
Cyclooxygenase-2 (COX-2) Is Frequently Expressed in Multiple Myeloma (MM) and Is Associated with Poor Outcome (2004) (1)
OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients (2021) (1)
[Monoclonal gammopathy of uncertain significance]. (1984) (1)
Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study (2022) (1)
Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (GEN503): Final Results of an Open-Label, Phase 1/2 Study (2017) (1)
Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia (2012) (1)
Prognostic factors and high dose chemotherapy (1998) (1)
Non-Hodgkin’s Lymphoma Refractory to First Line Therapy: Incidence, Associated Clinical and Histological Factors, and Outcome among 503 Newly Diagnosed Patients. (2007) (1)
Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results from the Imaging Sus-Study of the EMN02/HO95 MM Randomized Phase III Trial (2016) (1)
Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study (2017) (1)
Persistent Telomeric Loss and Functional Impairment of Ph-Negative Hematopoiesis after Successful Treatment of Chronic Myelogenous Leukemia (2008) (1)
On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877) (2020) (1)
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. (2022) (1)
Lenalidomide-Dexamethasone or Melphalan-Lenalidomide-Prednisone (MPR) or Cyclophosphamide-Prednisone-Lenalidomide (CPR) for Initial treatment of Real Life Elderly Patients with Newly Diagnosed Multiple Myeloma (2015) (1)
A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies (2016) (1)
Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice (2015) (1)
Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma (2017) (1)
[Kinetic and immunological considerations on the therapy of immunoproliferative disorders]. (1979) (1)
Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial (2022) (1)
INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA (2006) (1)
Can the dismal prognosis of patients with central nervous system plasma cell neoplasms be improved? (2021) (1)
Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia (2012) (1)
Identification of a new HLA-DRB1 allele in three members of an Italian family. (2004) (1)
Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. J. Clin. Med. 2020, 9, 2142 (2020) (1)
OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial (2022) (1)
COVID-19 AND MYELOMA (2022) (1)
Weekly Carfilzomib in combination with cyclophosphamide and dexamethasone (wCCyd) in patients (pts) with newly diagnosed Multiple Myeloma (NDMM): a phase 1/2 study of the European Myeloma Network Trialist Group (2015) (1)
Rituximab followed by localized radiation therapy in limited stage indolent non-Hodgkin's lymphoma: Preliminary results of a pilot study (2005) (1)
THE SURVIVAL OF TUMOR CELLS IN IGVH UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA IS HIGHLY DEPENDENT ON EXOGENOUS SIGNALS DELIVERED BY THE TUMOR MICROENVIRONMENT (2009) (0)
INCIDENCE OF INVASIVE ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANSPLANTATION PATIENTS: AN ITALIAN PROSPECTIC MULTICENTRE STUDY (2005) (0)
Outcome of first salvage therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, observational, non-interventional EMMOS study (2015) (0)
Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study (2019) (0)
TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
Retrospective Analysis on 290 Patients with Polycythemia Vera Referred to a Single Transfusion Centre: Diagnosis Revision According to WHO Criteria and Evaluation of Survival and Complications According to Prognostic Factors and Treatment (2008) (0)
The use of erythropoiesis stimulating agents (ESAs) is safe and effective in the management of anemia in myelofibrosis patients treated with Ruxolitinib Running title: Erythropoiesis-stimulating agents (ESAs) are effective in improving anemia in MF patients treated with Ruxolitinib without significa (0)
Myeloma cells drive the maturation of dendritic cells versus a Th2-promoting phenotype which impairs T-cell activation. (2003) (0)
Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
of 1175 patients overall survival in elderly myeloma treated with novel agents: analysis Complete response correlates with long-term progression-free and (2012) (0)
HBV reactivation in pOBI is influenced by detectable viremia at baseline rather than duration of prophylaxis with lamivudine (2017) (0)
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following Intensive Therapy and Autograft Correlates with the Type of Cells Grafted: A Survey on 1,347 Lymphoma Patients Receiving the High-Dose Sequential (HDS) Program. (2007) (0)
Post-Remission Treatment with Autologous or Allogeneic Bone Marrow Transplantation or Intensive Chemotherapy in Younger AML Patients: Long-Term Follow-up Results of the EORTC/Gimema AML-8A Study (2016) (0)
and is an independent predictor of poor outcome Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma (2013) (0)
Risk of Hepatitis B and Efficacy of Treatment with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplant. (2007) (0)
ROLE OF ALLOGRAFTING IN ACUTE LYMPHOBLASTIC LEUKEMIA: A 12 YEAR EXPERIENCE (2013) (0)
Droplet digital PCR improves minimal residual diseasemonitoring in mature lymphoid tumors (2014) (0)
Imatinib in 34 patients with steroid-refractory chronic graft-versus-host-disease: final evaluation of the second prospective trial, according to the NIH Consensus criteria for cGvHD (2012) (0)
Circulating MiR-130a monitoring in multiple myeloma patients and patients with extramedullary disease (2014) (0)
Array-Based Comparative Genomic Hybridization (Array-CGH) in Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL): Recurrent Imbalances within a Highly Heterogeneous Background of Genomic Disruption. (2005) (0)
Paroxysmal Nocturnal Hemoglobinuria With Budd-Chiari Syndrome Treated With Complement Inhibitor Eculizumab; A Case Report (2013) (0)
Met Over-Expression Is a Prognostic Factor for Myeloma Patients Treated with Novel Agents (2009) (0)
CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells. (2006) (0)
LONG TERM FOLLOW UP OF A COMPARISON OF NONMYELOABLATIVE ALLOGRAFTING WITH AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2009) (0)
A retrospective real-life analysis of chronic myeloid leukemia patients in suboptimal response to imatinib: three centres experience. (2012) (0)
C011 Marked telomere loss following autologous stem cell transplantation may be predictive for the onset of secondary myelodysplastic syndrome/acute leukemia (2007) (0)
Telomeres Shorten During Chronic Lymphocytic Leukemia(cll) Evolution: An Analysis on 88 Cases (2012) (0)
Intensified therapy with stem cell support for patients over age 60 (1998) (0)
Standard Treatment in Elderly Myeloma Patients Dose-Intensive Melphalan With Stem Cell Support (MEL100) Is Superior to (2010) (0)
CHROMOSOMAL ABNORMALITIES AND IMMUNOPHENOTYPE IN ELDERLY MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS ENTERED IN A PROSPECTIVE RANDOMIZED TRIAL OF VELCADE-MELPHALAN-PREDNISONE AND THALIDOMIDE VS VELCADE-MELPHALAN-PREDNISONE (2010) (0)
Immunoglobulin (Ig) Repertoire in Multiple Myeloma: High Frequency of Recurrent Aminoacid Substitutions in the FR2 and CDR2 (2006) (0)
Telomere Length Has Prognostic Impact in B-Cell Chronic Lymphocytic Leukemia (B-CLL). (2004) (0)
Co-Culture of Myeloma and Endothelial Cells: Defibrotide Downregulates Heparanase and Pro-Angiogenic Growth Factors. (2007) (0)
Recombinant interferon-gamma in a patient with multiple myeloma. (1994) (0)
The association of dexamethasone + simvastatin to overcome environment-mediated chemoresistance of chronic lymphocytic leukemia (CLL) cells (2014) (0)
Myeloma and related disorders. (1994) (0)
522PProof-of-concept of a risk calculator of chemotherapy induced (febrile) neutropenia (CIN/FN) based on real-world evidence (Monitor-GCSF study) (2017) (0)
emerging role for reduced intesity allotrasplant in multiple myeloma (2009) (0)
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells. (2006) (0)
DROPLET DIGITAL PCR (DDPCR) AND REAL-TIME PCR (RQ-PCR): A HEAD TO HEAD COMPARISON FOR MRD DETECTION IN MYELOMA (MM) MANTLE CELL LYMPHOMA (MCL) AND FOLLICULAR LYMPHOMA (FL) (2014) (0)
P932: ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY (2022) (0)
powerful myeloma staging system C-reactive protein and beta-2 microglobulin produce a simple and (2013) (0)
B094 Melphalan, Prednisone and Lenalidomide: Kinetics of Hematologic Toxicity and Time to Event Results (2009) (0)
Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (0)
Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors (2013) (0)
Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network (2019) (0)
TARGETING THE CXCR4 DOWNSTREAM SIGNALLING PATHWAYS TO REVERSE MICROENVIRONMENT PROTECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS (2016) (0)
Erratum to: Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) (2016) (0)
REDUCED INTENSITY/NON-MYELOABLATIVE ALLOGRAFTING FOR HIGH RISK CHRONIC LYMPHOCYTIC LEUKEMIA (2008) (0)
Prolonged Survival of Lymphoma Patients Achieving Complete Remission Following High-Dose Sequential Chemotherapy and Autograft (HDS Program): A GITIL (Gruppo Italiano Terapie Innovative Nei Linfomi) Retrospective Study on 1,266 Patients. (2006) (0)
LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) (2008) (0)
Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort (2015) (0)
Efficacy of Recombinant Erythropoietin + 13-cis Retinoic Acid + Dihydroxylated Vitamin D3 in the Treatment of Anemia of Low-Intermediate Risk Myelodysplastic Syndrome Patients. (2004) (0)
Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/Refractory Multiple Myeloma and 17p Deletion (2022) (0)
The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy (2014) (0)
B-Chronic lymphocytic leukaemia with aberrant expression of CD103: analysis of prognostic factors (2013) (0)
Characteristics of the Immunoglobulin Heavy Chain (IgH) Rearrangement in Multiple Myeloma (MM): An Analysis On 308 Cases. (2009) (0)
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORYACTIVITY OF ZOLEDRONIC ACID (2004) (0)
F15 Treatment of elderly patients with multiple myeloma (2009) (0)
2.28 Identification by Serological Proteome Analysis (SERPA) of Novel Tumor Associated Antigens in Chronic Lymphocytic Leukemia (CLL) (2011) (0)
A097 PAD-MEL100-LP-L in Elderly Untreated Myeloma Patients (2009) (0)
B457 AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3B (2009) (0)
ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
COMPARISON Among Citology, Histology, and FLOW Cytometry IN Evaluating Blast VALUES IN Myelodysplatic Syndromes (MDS). Survey FROM the Italian “PIEMONTE MDS REGISTRY” (2010) (0)
Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant. (2005) (0)
IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series (2019) (0)
immunity on short-term incubation with zoledronic acid Enhanced ability of dendritic cells to stimulate innate and adaptive (2013) (0)
Molecular mechanisms underlying CLL biology and response to treatment S 867 MULTIPLE MECHANISMS OF KRAS ACTIVATION IN TRISOMY 12 CHRONIC LYMPHOCYTIC LEUKEMIA (2019) (0)
Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]. (2022) (0)
INTENSIFIED TREATMENT WITH CIRCULATING PROGENITOR-CELL (CPC) SUPPORT IN MULTIPLE-MYELOMA - SEQUENTIAL CYCLOPHOSPHAMIDE MELPHALAN (1994) (0)
ituximab Induces Effective Clearance of Minimal esidual Disease in Molecular Relapses of Mantle ell Lymphoma (2006) (0)
Mixed lymphocyte reaction in human monoclonal gammopathies (1983) (0)
CYTOFLUORIMETRIC MONITORING OF MINIMAL RESIDUAL DISEASE CAN PREDICT CLINICAL REMISSION IN MULTIPLE MYELOMA PATIENTS UNDERGOING NON MYELOABLATIVE ALLOGENEIC TRANSPLANTATION (2002) (0)
Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide (2019) (0)
Bortezomib-Based Transplantation and Consolidation Therapy Followed by Lenalidomide Maintenance for Newly Diagnosed Multiple Myeloma (2020) (0)
A141 Enoxaparin Versus Aspirin Versus Low-Fixed-Dose Warfarin in MM Patients Treated Up Front with Thalidomide (2009) (0)
Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study (2019) (0)
Subject Index, Vol. 78, 1987 (1987) (0)
Risk of Early Severe Infections in Newly Diagnosed Multiple Myeloma Patients Treated with Novel Agents: A Pooled Analysis (2020) (0)
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals (2010) (0)
HashClone: a new tool to quantify the minimal residual disease in B-cell lymphoma from deep sequencing data (2017) (0)
HIF-1α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target (2016) (0)
Advanced age, organ damage and adverse events negatively affect survival of myeloma patients receiving novel agents: A meta-analysis of 1435 individual patient data from 4 randomized clinical trials (2012) (0)
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2014) (0)
Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
[Mixed IgM kappa-IgM lambda cryoglobulinemia with a double monoclonal serum component. A case report]. (1995) (0)
HIF-1a is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia (2019) (0)
PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY (2019) (0)
Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Mye (2021) (0)
2.37 Accelerated Activity of the Mevalonate Pathway Supports the Immune Escape and Multidrug- Resistance Phenotype of IGHV Unmutated Chronic Lymphocytic Leukemia Cells (2011) (0)
IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin (2010) (0)
Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial (2020) (0)
MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation. (2006) (0)
Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells (2014) (0)
Autologous transplant for myeloma: when the old meets the new (2017) (0)
Hematopoietic Cell Transplantation Comorbidity Index As Prognostic Variable in Patients with Invasive Fungal Infections (2015) (0)
Breakdown of RNA and protein synthesis template stability in proliferating and non proliferating human myeloma cells. (1977) (0)
Molecular Pathways Responsible for Adaptive Resistance to Single-Checkpoint Inhibition May Reveal Biomarkers and Immunotherapy Targets in Multiple Myeloma Patients (2017) (0)
[Kinetic and immunological studies in human myeloma: clinical implications (author's transl)]. (1979) (0)
NONMYELOABLATIVE ALLOGRAFTING OR AUTOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (2007) (0)
A Maintenance Therapy with Differentiating Agents and Low-Dose Chemotherapy Increases Remission Duration and Survival in High Risk AML and MDS Patients. (2005) (0)
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells (2011) (0)
PF579 TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS‘ CHARACTERISTICS IN MULTIPLE MYELOMA (2019) (0)
First comparison between Multicolor Flow Cytometry and droplet digital PCR for tumor burden quantification at baseline in mantle cell lymphoma (2016) (0)
Different pathogenesis of thalidomide neuropathy in multiple myeloma. (2002) (0)
A092 RMPT in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial (2009) (0)
Subject Index, Vol. 62, 1992 (2004) (0)
Bone Marrow-Derived Cell Mobilization with G-CSF and GM-CSF in Patients with Acute Myocardial Infarction: A Pilot Study on Feasibility, Safety and Efficacy. (2004) (0)
early plasma-cell differentiation and c-myc activation The human myeloma cell line LP-1: a versatile model in which to study (2011) (0)
ATP-Binding-Cassette A1 Regulates Extracellular Isopentenyl Pyrophosphate Release and Vγ9Vδ2 T-Cell Activation By Dendritic Cells (2016) (0)
Long Term Follow-up of a Population of Low-Intermediate Risk Myelodisplastyc Syndrome Patients Treated with a Combination of Recombinant Erythropoietin, 13-Cis-Retinoic Acid and Dihydroxylated Vitamin D3 Confirms the Positive Role of Erythroid Response on Survival (2010) (0)
REGULATION OF HIF-1 IN TP53 DISRUPTED CLL CELLS AND ITS INHIBITION AS A STRATEGY TO OVERCOME FLUDARABINE RESISTANCE (2017) (0)
P-268: INSURE: a global pooled analysis of patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with ixazomib-lenalidomidedexamethasone (IRd) in routine clinical practice (2022) (0)
INCIDENCE OF HHV-6 AFTER NONMYELOABLATIVE HSCT IN REFRACTORY MALIGNANCIES (2007) (0)
Induction with New Drugs and Planned Autologous Followed by Non-Myeloablative Allogeneic Transplantation in Newly Diagnosed Myeloma. (2009) (0)
PS1319 MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES (2019) (0)
EVIDENCE OF THE GRAFT VERSUS TUMOR EFFECT AFTER REDUCED INTESITY TRANSPLANT (2008) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects (2022) (0)
A105 A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients (2009) (0)
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma (2003) (0)
Chromosomal Abnormalities of Plasma Cells and Correlation With Immunophenotype in Multiple Myeloma (2007) (0)
Long-Term Monitoring of Cancer-Free Subjects Carrying Non-Lymphoma Associated bcl2/IgH Rearrangements (NLABR): Prolonged Persistence of Clonal Populations Potentially Related to Follicular Lymphoma (FL). (2004) (0)
Optimal Sequential Therapy in First Line and First Relapse of MM: A Post-Hoc Analysis (2015) (0)
MULTIPLE MYELOMA: CHROMOSOMAL ABNORMALITIES OF PLASMA CELLS AND CORRELATION WITH IMMUNOPHENOTYPE (2007) (0)
The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance (2015) (0)
Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients (2022) (0)
1596 Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia (CIN/FN) prophylaxis with biosimilar filgrastim and development of an outcomes risk calculator (MONITOR-GCSF study) (2015) (0)
Long-Term Outcome of High-Dose Sequential Chemotherapy with Autografting (i-HDS) in Follicular Lymphoma at Diagnosis: An Update of the Prospective Multicenter Consecutive Trial of the "Gruppo Italiano Trapianto Di Midollo Osseo" (Gitmo). (2004) (0)
Plasma cell expression of CD28 and CD40 correlates with peripheral T-cell defects in multiple myeloma (1997) (0)
602 Is There a Role for Allografting in Myeloma in the Era of New Drugs?: Long-Term Follow-Up of a Comparative Study (2011) (0)
Polyclonal Immunoglobulin ELevels Are CorrelatedwithHemoglobin Values and Overall Survival in Patients with Multiple Myeloma (2007) (0)
Translocation (14;16) Positive Multiple Myeloma: Clinical Features and Survival Outcomes of a High‐risk Population: MM‐257 (2018) (0)
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells (2016) (0)
Therapy of multiple myeloma. Italian Multiple Myeloma Study Group. (1990) (0)
Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant (2021) (0)
Minimal residual disease by next‐generation sequencing in mantle cell lymphoma: The bioinformatics tool HashClone (2017) (0)
SAFETY AND EFFICACY OF BORTEZOMIB IN RELAPSED MULTIPLE MYELOMA FOLLOWING REDUCED INTENSITY/NONMYELOABLATIVE CONDITIONINGS AND ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION (2006) (0)
Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients (2015) (0)
IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT (2000) (0)
MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma (2022) (0)
Targeting CCR1 for the Treatment of Osteolytic Bone Disease in Multiple Myeloma. (2007) (0)
IMATINIB DISCOTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS ON 28 UNSELECTED PATIENTS (2014) (0)
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. (2010) (0)
Cell kinetics and therapy in multiple myeloma: an update of the M83 protocol. (1989) (0)
INCIDENCE OF INVASIVE ASPERGILLOSIS IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS: AN ITALIAN PROSPECTIVE MULTICENTER STUDY (2004) (0)
Molecular a nd C linical R emissions i n M ultiple M yeloma: Role o f A utologous a nd A llogeneic T ransplantation of H ematopoietic C ells (1999) (0)
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS (2011) (0)
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) (2012) (0)
Patients with aaIPI 2-3 Diffuse Large B-Cell Lymphoma Achieve 75% Long-Term Survival Following First-Line Rituximab-Supplemented High-Dose Sequential Chemotherapy and Autograft: Final Results of the Prospective Phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) Trial. (2007) (0)
Progressive Telomere Shortening During the Natural History of Chronic Lymphocytic Leukemia (2011) (0)
Cyclosporin A and dipyridamole: an effective combination against the generation of cytotoxic T lymphocytes (CTL). (1992) (0)
700 RISK OF HEPATITIS B AND EFFICACY OF TREATMENT WITH LAMIVUDINE IN PATIENTS UNDERGOING ALLO-SCT (2008) (0)
Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients (2011) (0)
Minimal Residual Disease by Flow Cytometry and ASO-RQ-PCR in Myeloma Patients Receiving Lenalidomide Maintenance: A Pooled Analysis MRD and ASO-RQ-PCR in MM patients (2019) (0)
Invasive aspergillosis in allogeneic stem cell recipients: what are we doing? An Italian prospective study (2008) (0)
Promising Role of Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease (2018) (0)
A New Acute Monoblastic Leukemia Cell Line Expressing Vascular Endotelial Growth Factor (VEGF) -A and -D and VEGF Receptor-3 (Flt-4). (2006) (0)
Telomere Length of Hematopoietic Cells Following Autologous and Allogeneic Stem Cell Transplant (SCT) Reflects That of Grafted Cells: Can the Transplant of Younger Stem Cells Be Exploited To Rejuvenate Hematopoiesis?. (2007) (0)
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2009) (0)
Physician-Patient Relationship: Intervention Opportunities for Multiple Myeloma patients' Needs (2010) (0)
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) (2012) (0)
Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus (2021) (0)
Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years. (2005) (0)
PO-0641 MEDIASTINAL B-CELL LYMPHOMA IN PET-RITUXIMAB ERA: PROGNOSTIC IMPACT OF INITIAL RESPONSE AND RADIATION THERAPY (2012) (0)
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy (2019) (0)
A Phase III study of enoxaparin versus aspirin versus low-dose warfarin as thrombophylaxis for patients with newly diagnosed multiple myeloma treated up-front with thalidomide based-regimens (2009) (0)
ROLE OF ALLOGRAFTING IN HIGH RISK ACUTE MYELOID LEUKEMIA (2013) (0)
The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience (2019) (0)
Multiple Myeloma Cell-Osteoblast Interaction Results in Impaired Bone Formation. (2007) (0)
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (2011) (0)
Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs (2018) (0)
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) (2011) (0)
Hevylite and Freelite Tests in Newly Diagnosed Multiple Myeloma: Clinical Utility and Correlations with Clinical Features (2016) (0)
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells (2011) (0)
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials (2022) (0)
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis (2009) (0)
Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO. (2021) (0)
Low Dose TBI Based Nonmyeloablative Conditionings for Allografting in Multiple Myeloma: Impact of Disease Status at Transplant. (2004) (0)
Met mRNA value predicts outcome in multiple myeloma patients (2010) (0)
PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS (2022) (0)
Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies RUNNING HEAD : Chr 1 abnormalities in MM treated with new drugs (2014) (0)
Retrospective study of thalidomide plus dexamethasone versus conventional chemotherapy in the relapsed multiple myeloma patient and the study of melphalan and prednisone versus melphalan, prednisone, and thalidomide (2009) (0)
Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies (2018) (0)
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN MULTIPLE MYELOMA PATIENTS FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (2007) (0)
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma (2020) (0)
Retrospective analysis on R‐DHAP/OX and ASCT as salvage treatment for relapsed/refractory high‐risk follicular lymphoma (2017) (0)
Management of myeloma: an Italian perspective. (2011) (0)
Prognostic Role of Transfusion Requirement and Validation of the IPSS Prognostic System in Myelodisplastic Syndromes. (2006) (0)
Candidate drug BIBR1532 induces telomere shortening and growth inhibition in lymphoid cell lines. (2004) (0)
Oncogenes in the Pathogenesis of Multiple Myeloma (1996) (0)
High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease (2010) (0)
Thymic Function Following Nonmyeloablative Allografting for the Treatment of Hematological Malignancies (2008) (0)
MYD88L265P MUTATION DETECTION IN WALDENSTRÖM MACROGLOBULINEMIA BY DROPLET DIGITAL PCR: MINIMAL RESIDUAL DISEASE MONITORING AND CHARACTERIZATION ON CIRCULATING FREE DNA (2016) (0)
KAPOSI'S SARCOMA DUE TO ENDOGENOUS HHV-8 REATVIATION IN NON MYELOABLETIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (2002) (0)
MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study (2009) (0)
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia (2014) (0)
TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
human monoclonal gammopathies: correlation with tumor cell kinetics Decreased ecto-5'nucleotidase activity of peripheral blood lymphocytes in (2011) (0)
Fetal hemoglobin heterogeneity in Brazilian newborns and beta-thalassemia homozygotes. (1989) (0)
A Score Model for Predicting Unsuccessful or Sub-Optimal Peripheral Blood Stem Cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction Therapy and Cyclophosphamide Plus G-CSF As Mobilizing Regimen, (2011) (0)
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT BY FLOW CYTOMETRY FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES (2006) (0)
Sequential cyclophosphamide-melphalan (CM) with circulating progenitor cell (CPC) support in multiple myeloma (1995) (0)
Contents, Vol. 78, 1987 (1987) (0)
[Multiple myeloma. Mechanisms of proliferation and neoplastic progression and their clinical implications]. (1991) (0)
AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET (2016) (0)
Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry (2012) (0)
Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications. (2006) (0)
The Activity of Spanish and Italian Myeloma Groups (2009) (0)
PCR-Detectable N onneoplastic B cl-2/IgH R earrangements A re Common i n N ormal S ubjects a nd C ancer P atients a t D iagnosis but R are i n S ubjects T reated W ith C hemotherapy (2003) (0)
IMMUNE RECONSTITUTION OF THE T CELL COMPARTMENT IN HEMATOLOGICAL MALIGNANCIES FOLLOWING ALLOGENEIC NON MYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (2007) (0)
patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies (2018) (0)
Disease and Comorbidity Status Predict Outcome after Nonmyeloablative Allografting for Advanced Haematological Malignancies. (2007) (0)
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino (2019) (0)
Low dose TBI based non myeloablative allografting for advanced hematological malignancies: A multicenter experience. (2003) (0)
Impact of complete response on progression-free survival and overall survival in newly diagnosed myeloma patients treated with autologous stem cell transplantation or conventional chemotherapy: results of a pooled analysis of 5 phase III trials (2015) (0)
FISH and immunophenotype in elderly untreated Multiple Myeloma patients entered in a prospective randomized trial of Velcade-Melphalan-Prednisone and Thalidomide vs Velcade-Melphalan-Prednisone (2010) (0)
Phenotypic and functional analyses of peripheral blood T cells in women with recurrent spontaneous abortion in early stages of pregnancy (2007) (0)
P-065: CyTOF and single cell RNA sequencing reveal altered T cell phenotypes in Multiple Myeloma patients: implications for immunotherapy (2021) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance (2021) (0)
Maintenance Treatment with Recombinant Interferon Alfa-2b Prolongs Remission and Survival in Patients with Multiple Myeloma Responding to Induction Chemotherapy (1992) (0)
PLASMA CELL LABELING INDEX, BETA 2-MICROGLOBULIN, AND C-REACTIVE PROTEIN :WHATH IS THE BEST COMBINATION FOR MYELOME PROGNOSIS ? AUTHORS' RESPONSE (1993) (0)
DIFFERENT COMPOSITION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS BETWEEN PERIPHERAL BLOOD AND BONE MARROW: BIOLOGICAL AND CLINICAL IMPLICATIONS (2016) (0)
PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS (2019) (0)
Heavy+Light Chain and Free Light Chain Assays at Baseline and During Follow-up in EMN02/HO95 Multiple Myeloma Clinical Trial (2017) (0)
Telomere Length of Hematopoietic Cells in Long-Term Post-Autograft Survivors: No Evidence of Accelerated Replicative Cell Senescence Despite the Persistent Reduction of Both Committed and Immature Progenitor Cell Compartments. (2004) (0)
Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant. (2004) (0)
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES (2009) (0)
TARGETING HIF-1A AND ITS REGULATORY PATHWAYS AS A STRATEGY TO HAMPER LEUKEMIA-MICROENVIRONMENT INTERACTIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2017) (0)
The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice (2021) (0)
Regulation of HIF‐1 &agr; in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target: CLL‐101 (2018) (0)
REAL TIME PCR IN MULTIPLE MYELOMA: QUANTITATIVE ANALYSIS OF TUMOR CONTAMINATION OF STEM CELL HARVESTS (2001) (0)
Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials (2019) (0)
Anemia in the Elderly: not Always what it Seems (2016) (0)
monoclonal gammopathies: correlation with diagnosis and disease status Activated idiotype-reactive cells in suppressor/cytotoxic subpopulations of (2011) (0)
Contents Vol. 70, 2006 (2007) (0)
Incidence and Risk-Factors of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Chemotherapy and Autograft: A Long-Term Analysis on 307 Lymphoma Patients. (2004) (0)
Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients (2016) (0)
[Idiotypic study of human myeloma]. (1982) (0)
Risk of hepatitis B and efficacy of treatment with lamivudine in patients undergoing allo-SCT (2008) (0)
dyscrasias Mutational activation of N- and K-ras oncogenes in plasma cell (2011) (0)
177 INVITED New drugs (2007) (0)
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcome (2011) (0)
A442 Role of Comorbidities in Multiple Myeloma Patients Receiving RIC Allograft (2009) (0)
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) (2012) (0)
[Anatomy of a pedagogical sequence]. (2000) (0)
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells (2007) (0)
Subject Index Vol. 70, 2006 (2007) (0)
CLL-220: Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib (2020) (0)
Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multip (2015) (0)
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. (2022) (0)
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients (2018) (0)
Chromosome 1 abnormalities predict poor overall survival in elderly newly diagnosed multiple myeloma patients enrolled in the gimema-MM-03-05 randomized controlled trial (2012) (0)
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile. (2009) (0)
multiple myeloma: a reappraisal 18 years after (letter) Human myeloma cell lines as a tool for studying the biology of (2011) (0)
From cell biology to therapy: lenalidomide in untreated multiple myeloma (2009) (0)
Efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation at risk of hepatis B virus reactivation (2010) (0)
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome (2011) (0)
The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells (2014) (0)
Distribution of γδ T cells in patients with hematological malignancies (2009) (0)
Total lymphoid irradiation and antithymocyte globulin to reduce graft-versus-host disease after allografting in haematological malignancies: a GITMO experience (2011) (0)
Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL) (2010) (0)
miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients. (2012) (0)
New Combination Approaches for Multiple Myeloma (2009) (0)
Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities. (2009) (0)
S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mario Boccadoro?

Mario Boccadoro is affiliated with the following schools:

Mario Boccadoro's Academic­Influence.com Rankings

Mario Boccadoro's Degrees

Similar Degrees You Can Earn

Why Is Mario Boccadoro Influential?

Mario Boccadoro's Published Works

Published Works

What Schools Are Affiliated With Mario Boccadoro?

Mario Boccadoro's AcademicInfluence.com Rankings